Immunotherapy in the First-Line Setting in Wild-Type NSCLC
Treatment algorithms in the treatment of advanced non-small cell lung cancer (NSCLC) continue to evolve as new therapeutics show positive efficacy improvements. This review article summarizes the data for the use of immunotherapy for treatment in first-line stage IV NSCLC, organized by the following...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-11-01
|
| Series: | Current Oncology |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1718-7729/28/6/378 |
| _version_ | 1797505605141790720 |
|---|---|
| author | Marie-Hélène Denault Barbara Melosky |
| author_facet | Marie-Hélène Denault Barbara Melosky |
| author_sort | Marie-Hélène Denault |
| collection | DOAJ |
| description | Treatment algorithms in the treatment of advanced non-small cell lung cancer (NSCLC) continue to evolve as new therapeutics show positive efficacy improvements. This review article summarizes the data for the use of immunotherapy for treatment in first-line stage IV NSCLC, organized by the following four sections: single-agent immunotherapy, immunotherapy and chemotherapy, dual immunotherapy, and dual immunotherapy and chemotherapy. The results are summarized and tabulated. Finally, application of the trial data is illustrated in four clinical scenarios depending on the programmed death-ligand 1 (PD-L1) expression levels. Single checkpoint inhibitors have become an easy and excellent treatment in patients whose tumors have high PD-L1 expression. Adding chemotherapy to immunotherapy benefits our patients. Immunotherapy, with or without chemotherapy, is now the standard of care in the first-line setting in patients without EGFR, ALK, or ROS driver mutations. |
| first_indexed | 2024-03-10T04:21:00Z |
| format | Article |
| id | doaj.art-81a712c7214a45ba90c8938de6cff35c |
| institution | Directory Open Access Journal |
| issn | 1198-0052 1718-7729 |
| language | English |
| last_indexed | 2024-03-10T04:21:00Z |
| publishDate | 2021-11-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Current Oncology |
| spelling | doaj.art-81a712c7214a45ba90c8938de6cff35c2023-11-23T07:50:14ZengMDPI AGCurrent Oncology1198-00521718-77292021-11-012864457447010.3390/curroncol28060378Immunotherapy in the First-Line Setting in Wild-Type NSCLCMarie-Hélène Denault0Barbara Melosky1BC Cancer, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, CanadaBC Cancer, Vancouver Centre, 600 West 10th Avenue, Vancouver, BC V5Z 4E6, CanadaTreatment algorithms in the treatment of advanced non-small cell lung cancer (NSCLC) continue to evolve as new therapeutics show positive efficacy improvements. This review article summarizes the data for the use of immunotherapy for treatment in first-line stage IV NSCLC, organized by the following four sections: single-agent immunotherapy, immunotherapy and chemotherapy, dual immunotherapy, and dual immunotherapy and chemotherapy. The results are summarized and tabulated. Finally, application of the trial data is illustrated in four clinical scenarios depending on the programmed death-ligand 1 (PD-L1) expression levels. Single checkpoint inhibitors have become an easy and excellent treatment in patients whose tumors have high PD-L1 expression. Adding chemotherapy to immunotherapy benefits our patients. Immunotherapy, with or without chemotherapy, is now the standard of care in the first-line setting in patients without EGFR, ALK, or ROS driver mutations.https://www.mdpi.com/1718-7729/28/6/378NSCLCPD-L1first-lineimmunotherapynon-small cell lung cancersquamous |
| spellingShingle | Marie-Hélène Denault Barbara Melosky Immunotherapy in the First-Line Setting in Wild-Type NSCLC Current Oncology NSCLC PD-L1 first-line immunotherapy non-small cell lung cancer squamous |
| title | Immunotherapy in the First-Line Setting in Wild-Type NSCLC |
| title_full | Immunotherapy in the First-Line Setting in Wild-Type NSCLC |
| title_fullStr | Immunotherapy in the First-Line Setting in Wild-Type NSCLC |
| title_full_unstemmed | Immunotherapy in the First-Line Setting in Wild-Type NSCLC |
| title_short | Immunotherapy in the First-Line Setting in Wild-Type NSCLC |
| title_sort | immunotherapy in the first line setting in wild type nsclc |
| topic | NSCLC PD-L1 first-line immunotherapy non-small cell lung cancer squamous |
| url | https://www.mdpi.com/1718-7729/28/6/378 |
| work_keys_str_mv | AT mariehelenedenault immunotherapyinthefirstlinesettinginwildtypensclc AT barbaramelosky immunotherapyinthefirstlinesettinginwildtypensclc |